BioCentury
ARTICLE | Company News

AstraZeneca, Pfizer deal

September 5, 2016 7:00 AM UTC

Pfizer will acquire AstraZeneca’s small molecule anti-infectives business. The unit includes approved drugs Zavicefta ceftazidime/ avibactam, Zinforo ceftaroline fosamil and Merrem/Meronem meropenam, as well as Phase II candidates, ATM-AVI and CXL.

AZ will receive $550 million in cash up front and $175 million due in January 2019. AZ is also eligible for up to $250 million in milestones and up to $600 million in “sales-related payments,” plus double-digit tiered royalties on sales of Zavicefta and ATM-AVI. ...